title: Targeting gastrin-releasing peptide receptors for cancer treatment.
abstract: Growth factor receptors play critical roles in cancer cell proliferation and progression. A number of such receptors have been targeted for cancer treatment by either a monoclonal antibody or a specifically designed small molecule to inhibit the receptor function. Bombesin/gastrin-releasing peptide receptors (BN/GRP-Rs) are expressed in a variety of cancer cells and have limited distribution in normal human tissue. Inhibition of BN/GRP-Rs has been shown to block small cell lung cancer growth in vitro. Early phase clinical trials targeting human GRP-R showed anti-cancer activity. This review will focus on the study of the distribution of BN/GRP-Rs in normal and malignant tissues, and various approaches to targeting BN-GRP-Rs for cancer diagnosis and treatment.
authors.affiliation: Division of Blood and Marrow Transplantation, Department of Medicine and Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA 92093-0960, USA.
authors.forename: Jiehua
authors.initials: J
authors.lastname: Zhou
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.forename: Michael
authors.initials: M
authors.lastname: Mokotoff
authors.forename: Edward D
authors.initials: ED
authors.lastname: Ball
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D020320:Oligoribonucleotides, Antisense / Q000627:therapeutic use; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D020320:Oligoribonucleotides, Antisense; D018004:Receptors, Bombesin